Bolt Biotherapeutics, Inc. (BOLT)
6.08
+0.17
(+2.88%)
USD |
NASDAQ |
Nov 13, 16:00
6.20
+0.12
(+1.97%)
Pre-Market: 19:59
Bolt Biotherapeutics Enterprise Value : 18.99M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 18.99M |
| November 12, 2026 | 18.63M |
| November 11, 2026 | 19.38M |
| November 10, 2026 | 19.47M |
| November 09, 2026 | 19.75M |
| November 06, 2026 | 19.98M |
| November 05, 2026 | 19.64M |
| November 04, 2026 | 19.98M |
| November 03, 2026 | 20.05M |
| November 02, 2026 | 19.34M |
| October 30, 2026 | 20.09M |
| October 29, 2026 | 19.60M |
| October 28, 2026 | 20.07M |
| October 27, 2026 | 19.62M |
| October 26, 2026 | 20.09M |
| October 23, 2026 | 19.40M |
| October 22, 2026 | 14.92M |
| October 21, 2026 | 14.81M |
| October 20, 2026 | 15.18M |
| October 19, 2026 | 14.60M |
| October 16, 2026 | 14.51M |
| October 15, 2026 | 15.03M |
| October 14, 2026 | 14.47M |
| October 13, 2026 | 15.12M |
| October 12, 2026 | 15.03M |
| Date | Value |
|---|---|
| October 09, 2026 | 14.75M |
| October 08, 2026 | 13.76M |
| October 07, 2026 | 13.65M |
| October 06, 2026 | 13.45M |
| October 05, 2026 | 13.43M |
| October 02, 2026 | 13.33M |
| October 01, 2026 | 13.45M |
| September 30, 2026 | 13.82M |
| September 29, 2026 | 10.76M |
| September 28, 2026 | 10.49M |
| September 25, 2026 | 10.72M |
| September 24, 2026 | 10.74M |
| September 23, 2026 | 10.86M |
| September 22, 2026 | 10.97M |
| September 21, 2026 | 10.74M |
| September 18, 2026 | 10.68M |
| September 17, 2026 | 10.27M |
| September 16, 2026 | 10.82M |
| September 15, 2026 | 11.59M |
| September 14, 2026 | 11.49M |
| September 11, 2026 | 11.43M |
| September 10, 2026 | 11.01M |
| September 09, 2026 | 10.91M |
| September 08, 2026 | 11.26M |
| September 04, 2026 | 11.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Caribou Biosciences, Inc. | -29.36M |
| Oncolytics Biotech, Inc. | 46.90M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 1.897B |
| Anixa Biosciences, Inc. | 75.65M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.422M |
| Total Expenses (Quarterly) | 4.422M |
| EPS Diluted (Quarterly) | -2.249 |
| Earnings Yield | -246.1% |
| Normalized Earnings Yield | -230.78 |